Life sciences’ great showcase solution for generative AI: adverse event case intake

In developed economies, it is expected, and assumed, that any authorized drug or medicinal therapy designed for human use is unequivocally safe. Pharmacovigilance processes – the discipline of continuously monitoring the effects of drugs once on the market – are designed to uphold that position over time, once a product has been authorized for patient consumption.

Approaches to post-market Safety monitoring have changed little in decades, however, despite soaring volumes of available information – submitted in an increasing array of formats, via a proliferating range of channels.